Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'

 
• By Anju Ghangurde

The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.

COVID-19 Vaccine. Corona Virus SARS-CoV-2, 2019 nCoV virus destruction. A vaccine against coronavirus disease 2019. Breakthrough in the Creating of a COVID-19 Vaccine.
Transparency About COVID-19 Vaccine Data Vital, Says Takeda Executive • Source: Shutterstock

More from Business

More from Scrip